Erin C. answered 05/29/20
Residency trained clinical pharmacist
- Statins may cause hepatotoxicity (monitor LFTs upon initiation of therapy and periodically while patient is taking medication, rhabdomyolysis or myopathy (obtain CPK in any patient with symptoms suggestive of myopathy (pain, tenderness, stiffness, cramping, weakness, or generalized fatigue), and is contraindicated in pregnancy (may cause congenital defects).
- Adequate contraception is recommended if an HMG-CoA reductase inhibitor is required in females of reproductive potential. Females planning a pregnancy should discontinue the HMG-CoA reductase inhibitor 1 to 2 months prior to attempting to conceive. Simvastatin should be discontinued immediately if an unplanned pregnancy occurs during treatment.
- Simvastatin will be most effective if taken at night because this is when cholesterol is made.
- Discontinue use until symptoms can be evaluated; evaluate patient for conditions that may increase the risk for muscle symptoms (eg, hypothyroidism, reduced renal or hepatic function, rheumatologic disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D deficiency, or primary muscle diseases). Upon resolution, resume the original or lower dose of simvastatin. If muscle symptoms recur, discontinue simvastatin use. After muscle symptom resolution, may then use a low dose of a different statin (usually pravastatin is better tolerated in patients with muscle pain); gradually increase if tolerated.
- Fasting lipid profile should be rechecked 4 to 12 weeks after starting therapy and every 3 to 12 months thereafter.
- LDL<100
- TC <200
- TG <150
- HDL >40